Convalescent plasma treatment of severe COVID-19: a propensity score–matched control study

[1]  Harnish Mukesh Naik,et al.  Sex, age, and hospitalization drive antibody responses in a COVID-19 convalescent plasma donor population. , 2020, The Journal of clinical investigation.

[2]  H. Harapan,et al.  Antibody-based immunotherapeutics and use of convalescent plasma to counter COVID-19: advances and prospects , 2020, Expert opinion on biological therapy.

[3]  R. Bruno,et al.  Mortality reduction in 46 severe Covid-19 patients treated with hyperimmune plasma. A proof of concept single arm multicenter trial. , 2020, Haematologica.

[4]  Patrick W. Johnson,et al.  Safety Update , 2020, Mayo Clinic Proceedings.

[5]  A. Firpo,et al.  SARS-CoV-2 infection induces robust, neutralizing antibody responses that are stable for at least three months , 2020, medRxiv.

[6]  M. M. van der Eerden,et al.  Convalescent Plasma for COVID-19. A randomized clinical trial , 2020, medRxiv.

[7]  S. Lee,et al.  Antibody Responses to SARS-CoV-2 at 8 Weeks Postinfection in Asymptomatic Patients , 2020, Emerging infectious diseases.

[8]  Patrick W. Johnson,et al.  Early safety indicators of COVID-19 convalescent plasma in 5,000 patients. , 2020, The Journal of clinical investigation.

[9]  L. Ren,et al.  Effect of Convalescent Plasma Therapy on Time to Clinical Improvement in Patients With Severe and Life-threatening COVID-19: A Randomized Clinical Trial. , 2020, JAMA.

[10]  R. Bruno,et al.  Mortality reduction in 46 severe Covid-19 patients treated with hyperimmune plasma. A proof of concept single arm multicenter interventional trial , 2020, medRxiv.

[11]  S. W. Long,et al.  Treatment of Coronavirus Disease 2019 (COVID-19) Patients with Convalescent Plasma , 2020, The American Journal of Pathology.

[12]  S. W. Long,et al.  Treatment of COVID-19 Patients with Convalescent Plasma , 2020, The American Journal of Pathology.

[13]  C. Cunningham-Rundles,et al.  A serological assay to detect SARS-CoV-2 seroconversion in humans , 2020, Nature Medicine.

[14]  Y. Shoenfeld,et al.  Convalescent plasma in Covid-19: Possible mechanisms of action , 2020, Autoimmunity Reviews.

[15]  M. Ramakers,et al.  High incidence of venous thromboembolic events in anticoagulated severe COVID‐19 patients , 2020, Journal of Thrombosis and Haemostasis.

[16]  Eun Ji Kim,et al.  Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area. , 2020, JAMA.

[17]  Kaijun Jiang,et al.  SARS‐CoV‐2 Seroconversion in Humans: A Detailed Protocol for a Serological Assay, Antigen Production, and Test Setup , 2020, Current protocols in microbiology.

[18]  T. Lv,et al.  Treatment with convalescent plasma for COVID‐19 patients in Wuhan, China , 2020, Journal of medical virology.

[19]  Y. Yazdanpanah,et al.  Severe Acute Respiratory Syndrome Coronavirus 2−Specific Antibody Responses in Coronavirus Disease Patients , 2020, Emerging infectious diseases.

[20]  Yan Peng,et al.  Effectiveness of convalescent plasma therapy in severe COVID-19 patients , 2020, Proceedings of the National Academy of Sciences.

[21]  J. Guarner,et al.  Convalescent Plasma to Treat COVID-19: Possibilities and Challenges. , 2020, JAMA.

[22]  Philip L. Felgner,et al.  A serological assay to detect SARS-CoV-2 seroconversion in humans , 2020, medRxiv.

[23]  Arturo Casadevall,et al.  The convalescent sera option for containing COVID-19. , 2020, The Journal of clinical investigation.

[24]  J. Xiang,et al.  Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study , 2020, The Lancet.

[25]  Yuan Shi,et al.  Convalescent plasma as a potential therapy for COVID-19 , 2020, The Lancet Infectious Diseases.

[26]  Lei Liu,et al.  Antibody responses to SARS-CoV-2 in patients of novel coronavirus disease 2019 , 2020, medRxiv.

[27]  S. Murthy,et al.  Anti-Ebola therapy for patients with Ebola virus disease: a systematic review , 2019, BMC Infectious Diseases.

[28]  Dennis Andersson,et al.  A retrospective cohort study , 2018 .

[29]  S. Bewley,et al.  Lesbian and bisexual women's gynaecological conditions: a systematic review and exploratory meta‐analysis , 2016, BJOG : an international journal of obstetrics and gynaecology.

[30]  W. Lim,et al.  The Effectiveness of Convalescent Plasma and Hyperimmune Immunoglobulin for the Treatment of Severe Acute Respiratory Infections of Viral Etiology: A Systematic Review and Exploratory Meta-analysis , 2014, The Journal of infectious diseases.

[31]  Peter C Austin,et al.  A comparison of 12 algorithms for matching on the propensity score , 2013, Statistics in medicine.

[32]  Li Jianguo,et al.  Advances and prospects , 2014 .

[33]  Ariel Linden,et al.  Using balance statistics to determine the optimal number of controls in matching studies. , 2013, Journal of evaluation in clinical practice.

[34]  K. Yuen,et al.  Hyperimmune IV immunoglobulin treatment: a multicenter double-blind randomized controlled trial for patients with severe 2009 influenza A(H1N1) infection. , 2013, Chest.

[35]  E. Mohammadi,et al.  Barriers and facilitators related to the implementation of a physiological track and trigger system: A systematic review of the qualitative evidence , 2017, International journal for quality in health care : journal of the International Society for Quality in Health Care.

[36]  P. Austin.  American Journal of Epidemiology Practice of Epidemiology Statistical Criteria for Selecting the Optimal Number of Untreated Subjects Matched to Each Treated Subject When Using Many-to-one Matching on the Propensity Score , 2022 .

[37]  S. Hoffman,et al.  Meta-Analysis: Convalescent Blood Products for Spanish Influenza Pneumonia: A Future H5N1 Treatment? , 2006, Annals of Internal Medicine.

[38]  Frank Serafini.  Possibilities and Challenges , 2002 .

[39]  J. Maiztegui,et al.  IMPORTANCE OF DOSE OF NEUTRALISING ANTIBODIES IN TREATMENT OF ARGENTINE HAEMORRHAGIC FEVER WITH IMMUNE PLASMA , 1984, The Lancet.

[40]  E. Glaser.  The randomized clinical trial. , 1972, The New England journal of medicine.

[41]  R. Cecil.  Remarks on THE SERUM TREATMENT OF PNEUMONIA * , 1932, British medical journal.

[42]  M. Finland.  The Serum Treatment of Lobar Pneumonia , 1930 .